Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind study to evaluate the efficacy and safety of Avastin plus Roferon compared with placebo plus Roferon on overall survival and tumor assessment in nephrectomised patients with metastatic clear cell renal cell carcinoma.

Next Previous
Trial Profile

A randomised, double-blind study to evaluate the efficacy and safety of Avastin plus Roferon compared with placebo plus Roferon on overall survival and tumor assessment in nephrectomised patients with metastatic clear cell renal cell carcinoma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Interferon alpha-2a
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms AVOREN
  • Sponsors Roche

    • Most Recent Events

    • 19 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Apr 2010 Results published in Journal of Clinical Oncology.
    • 05 Mar 2010 Results of an indirect comparison of sunitinib vs bevacizumab + interferon-alpha-2a using results from this and another phase III trial (NCT00098657) were presented at ASCO 2010 Genitourinary Cancers Symposium.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top